WHO Pharmaceuticals Newsletter 2005, No. 04
(2005; 15 pages) Voir le document au format PDF
Table des matières
Ouvrir ce répertoire et afficher son contenuREGULATORY MATTERS
Fermer ce répertoireSAFETY OF MEDICINES
Afficher le documentAnti-TNF alpha products - New measures to prevent activation of latent tuberculosis
Afficher le documentBeta-2 agonists - Increased risks of asthma-related deaths
Afficher le documentCabergoline - Use linked to gambling
Afficher le documentCodeine & hydrocodeine - Akathisia with longterm use
Afficher le documentEzetimibe - Reports of muscle pain
Afficher le documentHydromorphone - Co-ingestion with alcohol harmful
Afficher le documentIbuprofen - Reports of Stevens-Johnson syndrome
Afficher le documentIsotretinoin - Strengthened risk management programme
Afficher le documentTrastuzumab - Addition to chemotherapy increases toxicity
Afficher le documentVinca alkaloids - Intrathecal administration reported
Ouvrir ce répertoire et afficher son contenuFEATURE
 

Ibuprofen - Reports of Stevens-Johnson syndrome

Canada. Health Canada has received four reports of suspected ibuprofen-associated Stevens-Johnson syndrome between 1 January 1973 and 21 February 2005, according to the Canadian Adverse Reaction Newsletter. All four reports were received after April 2001 and involved patients aged 13.34 years who had received ibuprofen 200.1200 mg/day. The time to reaction onset ranged from the day of administration to about 15 days after ibuprofen initiation, and carbamazepine was also identified as a suspect drug in one report. At the time of the reports, the outcome was unknown for one patient and three of the patients had not recovered.

Reference:

Canadian Adverse Reaction Newsletter July 2005, No. 3.

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013